-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Pharmacological Research
European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)
Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer’s Disease Biomarkers, Behavioural and Psychiatric Symptoms of Dementia, Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, Cardiovascular Adverse Events, Clinical Diagnostic Criteria, Committee for Medicinal Products for Human Use (CHMP), Comparison IWG and NIA-AA Criteria for Clinical Diagnosis of Alzheimer´s Disease, Diagnostic Tests, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnostic Criteria, EMA Central Nervous System Working Party, EMA: European Medicines Agency, Enrichment of Study Populations, European Medicines Agency, European Medicines Agency (EMA), Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Guideline on Clinical Investigation of Medicines for Alzheimer’s Disease and Other Dementias, Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and Nine Other Dementias, International Organisations, International Programmes, International Working Group (IWG), Long-Term Efficacy and Safety Studies, Medical Research, Medicines Development, Medicines Mechanism of Action, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurological Adverse Events, Neurological Disorders, Novel Targets in Neurodegeneration, Ordering of Alzheimer's Disease Biomarkers, Pharmaceutical Industry, Pharmacological Research, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Psychiatric Adverse Events, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Safety and Efficacy Markers, Stratification of Subgroups (Clinical Trials), Target Discovery and Preclinical Validation, Therapeutic Target(s): Identification, Timely Diagnosis
|
Leave a comment
Big Data Portal for Alzheimer’s Dementia Drug Discovery (NIH / Synapse AMP-AD)
Summary The National Institutes of Health (NIH) in the USA has opened a public-private partnership online resource to facilitate neurodegenerative research and drug development. The launch of the Alzheimer’s Big Data Portal provides an open-source “public knowledge portal” for the … Continue reading →
Posted in Charitable Bodies, For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Accelerating Alzheimer's Research and Drug Development, Accelerating Medicine Partnership for Alzheimer's Disease (NIA-AMP AD) Target Discovery and Preclinical Validation Project, Accelerating Medicines Partnership (AMP), Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD), Alfred P. Sloan Foundation, Alzheimer’s Disease Biomarkers, Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative (ADNI), AMP-AD Program, Big Data, Big Data Portal for Alzheimer’s Dementia Drug Discovery, Big Pharma, Biomarkers, Biopharmaceutical Companies, Broad Institute of MIT and Harvard, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Cross-Sector Partnerships, Dementia Research, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Emory University, Foundation for the NIH (FNIH), Genetic Research, Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Global Open Data Initiative, Human Epigenome Atlas, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology (Seattle), International Alzheimer's Disease Research Portfolio (IADRP), International Collaborations, International Organisations, International Programmes, Market Failure (Dementia Research and Drug Development), Mayo Clinic in Jacksonville, Medical Research, Multidisciplinary Research Teams, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NIA Genetics of Alzheimer’s Data Storage Site (NIAGADS), NIH Big Data to Knowledge (BD2K) Initiative, NIH Network for Excellence in Neuroscience Clinical Trials, Non-Profit Collaborations, Novel Targets in Neurodegeneration, Open Data, Open Data and Big Data, Open Data in Health and Social Care, Open Data Learning Capacity and Culture, Open Data: Unlocking Innovation, Open Source Solutions, Pharmaceutical Industry, Pharmacological Research, Potential of Open Data in Health and Social Care, Pre-Competitive Collaboration, Precision Medicine Initiative, Preclinical Biomarkers in Alzheimer's Disease, Public-Private Partnership (PPP), Public-Private Partnerships, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Roadmap Epigenomics Project, Rush University Medical Center: Chicago, Sage Bionetworks, Synapse, Synapse Access and Compliance Team, Target Discovery and Preclinical Validation, Technology Transfer, Temporal Evolution of Alzheimer’s Disease Biomarkers, Therapeutic Target(s): Identification, Translational Research, Transparency and Open Data, United States, University of California, University of Florida, US National Institute of Aging, US National Institutes of Health (NIH), USA
|
Leave a comment
UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has announced the launch of the Drug Discovery Alliance, a £30 million network of research centres working collaboratively on research to discover potential cures, or at least disease modifying treatments, for Alzheimer’s Disease and other forms … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, For Researchers (mostly), In the News, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Alzheimer’s Research UK Drug Discovery Institute, Alzheimer’s Research UK’s Drug Discovery Alliance, Big Pharma, Cambridge Biomedical Campus, Cambridge Drug Discovery Institute, Cambridge University, Clinical Research Networks, Collaborative Drug Discovery Programmes, Commissioning Research, Crowd-Sourced Information, Crowdsourcing, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Dr Laura Phipps: Alzheimer’s Research UK, Drug Discovery Alliance, Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, Genetic Research, Genetic Triggers, Global Action Against Dementia, Global Clinical Development Fund, Global Context, Global Dementia Legacy Event, Global Leadership, Global Outlook, Gurdon Institute: University of Cambridge, Innovation in Genetics, International Collaborations, International Organisations, International Programmes, Knowledge Networks, Knowledge Translation, Medical Research, MIT Sloan School of Management: Model for Public-Private Partnerships in Funding Research, Multidisciplinary Research Teams, Networks, Networks and Alliances, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Oxford Drug Discovery Institute, Oxford University, Parallel Discovery of Alzheimer’s Therapeutics (MIT Sloan and University of California Model), Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmacological Research, Philanthropic Funding, Philanthropy, Prof. David Rubinsztein: Lead Academic Scientist at Cambridge Drug Discovery Institute, Prof. Giampietro Schiavo: Co-Lead Academic Scientist at UCL Drug Discovery Institute, Prof; Simon Lovestone: Co-Lead Academic Scientists at Oxford Drug Discovery Institute, Research Commitment, Research Consortia, Research Culture, Research Mapping, Research Networks, Research Programmes, Scientific Management Board of the Drug Discovery Institute, Stem Cell Research, Translational Research, UCL Drug Discovery Institute, University College London (UCL), University of Cambridge, University of Oxford
|
Leave a comment
Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has launched the Global Clinical Trials Fund (GCTF) to help finance trials which aim to translate discoveries in the lab into clinical treatments for the 830,000 people living with dementia in the UK. The GCTF aims … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Clinical Trials, Clinical Trials (Phase I Through Phase III), Clinical Trials and Treatment Assessments, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Commissioning Research, Dementia Consortium, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, GCTF: Global Clinical Trials Fund, Global Action Against Dementia, Global Clinical Trials Fund (GCTF), International Collaborations, International Organisations, International Programmes, Intervention Trials, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Non-Drug Intervention Trials, Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Research Commitment, Research Consortia, Research Culture, Research Programmes, Technology Transfer, Translational Research
|
Leave a comment
Second Global Dementia Legacy Event: Ottawa, September 11th/12th 2014 (Department of Health / Dementia Challenge / World Dementia Council / CIHR / AVIESAN)
Summary Canada and France are co-hosting the second Global Action Against Dementia Legacy Event in Ottawa (Canada) on September 11th – 12th 2014. This event will explore how to take advantage of partnership working and collaboration between industry and academia, … Continue reading →
Posted in Acute Hospitals, Community Care, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Universal Interest
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Academic-Industry Collaborations, Alain Beaudet: President of Canadian Institutes of Health Research (CIHR), Alice Wong: Minister of State (Seniors) in Canada, Alzheimer Society of Canada, AVIESAN: French National Alliance for Life Sciences and Health, •Alzheimer Society of Canada, Big Data, Biotechnology, Canada, Canada's Research Strategy for Alzheimer's Disease, Canada-France Legacy Event, Canadian Institutes of Health Research (CIHR), Challenge on Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia in Canada, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Dennis Gillings: Former World Dementia Envoy, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug-Development Pipeline, Faye Forbes (Living With Dementia), France, Free Open Access Journals, G7 Global Dementia Summit, G8 Dementia Summit, G8 Dementia Summit Agreements, G8 Summit on Dementia Communique, G8 Summit on Dementia Declaration, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Global Dementia Legacy Event on Academia-Industry Synergies, Global Leadership, Global Outlook, Incentives and Investment, Incentives for Drug Development, Innovation, Innovative Medicines Initiative, Institute of Health and Medical Research (Inserm), International Collaborations, International Programmes, Japan Legacy Event, Knowledge Networks, Knowledge Translation, Massachusetts Biotech Cluster: CONNECT, Matthew Dineen (Carer), Medical Devices, Networks, Networks and Alliances, Neurological Research, OECD Big Data and Sustainability Initiative for Large-Scale Research on Dementia, Open Access, Open Access Databases, Open Access Journals, Open Access Knowledge Resources, Open Access Research, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, Philippe Zeller: Ambassador of France to Canada, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Regulatory Barriers: Regulatory Environment, Removing Regulatory Barriers, Research and Innovation, Research Networks, Resource and Incentives, Second Global Dementia Legacy Event, Second Global Dementia Legacy Event (Ottawa: September 2014), The Honourable Rona Ambrose: Minister of Health (Canada), UK Legacy Event, USA Legacy Event, Venture Capital (Approach to Research), World Dementia Council, Yves Lévy: French National Institute of Health and Medical Research (Inserm) and Chairman of Aviesan (French National Alliance for Life Sciences and Health Care)
|
Leave a comment
Google’s “Moonshot Project” on Tackling Ageing (Financial Times / Reuters / BBC News / ICO / Health and Technology / HTN)
Summary Arthur Levinson, formerly of Genentech, has left Roche to avoid any potential conflict of interest in his role as chief executive of Google’s Calico start-up company. Calico recently agreed a $1.5bn alliance with AbbVie, a rival of Roche, to develop treatments for … Continue reading →
Posted in Assistive Technology, In the News, International, Management of Condition, Non-Pharmacological Treatments, Parkinson's Disease, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged 23andMe, AbbVie, Acute Kidney Injury (AKI), Age and Ageing, Age-Related Disease Research, Age-Related Neurodegenerative and Neurovascular Diseases, Ageing and Dementia, Ageing and Society, Ageing Population, Ageing Well, AI for Good Programme (Microsoft), AI for Health Programme (Microsoft), Arthur Levinson, Artificial Intelligence, Artificial Intelligence (AI), Attitudes to Ageing, Basline Study: Collection of Anonymous Genetic and Molecular Information, BBC Health News, Big Data, Big Pharma, BRAC, Compensation for Shaky Hands (Assistive Technology), Data Protection Act (1998), Data Protection Procurement Rules and Competition Rules (Potential Barriers to Information Sharing), Data Protection Procurement Rules and Competition Rules (Potential Barriers to Partnership Working), Data Sharing, Data Sharing Agreement, Data Sharing for Better Health, DeepMind Health, Diffusion of Innovation, Disease-Detecting Nanoparticles, Economist (Journal), Elizabeth Denham, Elizabeth Denham: Information Commissioner, Encouraging Innovation, Essential Tremor, Faculty of Law and Computer Laboratory: University of Cambridge, Financial Times, Fred Hutchinson Cancer Research Center (Seattle), FT.com, Genentech, Google, Google Ageing-Related Ambitions, Google Basline Study: Anonymous Genetic and Molecular Information, Google Health-Related Ambitions, Google Moonshot Projects, Google Moonshot Projects: Ageing-Related, Google X, Google X: Cutting-Edge Technology Projects, Google X: Potentially Revolutionary Innovation, Google's DeepMind, Google's Research Division: Google X, Google's Social Network: Google+, Google’s Calico, Google’s DeepMind and Royal Free Trust Data-Sharing Agreement, Google’s Health Portfolio, Health and Technology (Journal), Health Technology, Healthy Life Expectancy, HTN: Health Tech Newspaper, Human Longevity, Information Commissioner’s Office (ICO), Information Commissioner’s Website, Intelligent Retinal Imaging Systems (IRIS), International Collaborations, International Dementia Research Inventories, International Programmes, International Research, Lift Labs, Longevity, Novartis Foundation, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Data and Big Data, Open Science, Open Source Solutions, Partnership and Collaboration, Partnership Working, PATH, Pharmaceutical Industry, Pharmacological Research, Policies on Ageing, Preventative Care, Proactive Care, Reinventing Ageing, Research and Innovation, Reuters, Roche, Royal Free Hospital (London), Royal Free London NHS Trust, Royal Free NHS Foundation Trust, Science of Ageing, Seattle Children’s Research Institute, Smart Contact Lenses, Stabilization Technology: Tremor Cancellation, Streams app (Google’s DeepMind), Supporting Healthy Lifestyles, Tremor, Tremor and Other Hyperkinetic Movements, Tremor Cancellation Spoon (Stabilization Technology), Tremor-Cancelling Devices
|
Leave a comment
Dementia Consortium (Alzheimer’s Research UK)
Summary The Dementia Consortium has been established to fund academic dementia research experts from the UK and overseas in their efforts to develop early research findings concerning Alzheimer’s Disease, and other forms of dementia, into validated drug targets. “The Dementia … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, UK
|
Tagged ARUK: Alzheimer’s Research UK, Big Pharma, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Dementia Consortium, Dementia Research, Dementia Research Priorities, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Eisai Ltd, Eli Lilly, Fast-Tracking New Potential Treatments, Justin Bryans: MRC Technology, Lilly, MRC Technology, MRC Technology (Independent Life Science Technology Transfer Charity), MRCT: MRC Technology, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Technology Transfer, Translational Research
|
Leave a comment
Decline in Number of Clinical Trials for Alzheimer’s Disease (BBC News / Alzheimer’s Research & Therapy)
Summary More than 99% of drug trials for Alzheimer’s Disease during the past decade have failed. An article in the Alzheimer’s Research & Therapy journal discusses an issue which was perhaps the key focus of the Global Dementia Legacy Event. … Continue reading →
Posted in Alzheimer’s Disease International (ADI), Alzheimer’s Research UK, BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Standards, Universal Interest
|
Tagged Alzheimer’s Disease Clinical Trials, Amyloid Cascade Hypothesis, Anti-Amyloid Combination Therapy, Antidementia Drugs, Aston University, BBC Health News, Big Pharma, Brain Research, Cleveland Clinic Lou Ruvo Center for Brain Health: Las Vegas, Clinical Trials and Treatment Assessments, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Incentives for Drug Development, Neurological Research, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, R&D Productivity, Touro University Nevada College of Osteopathic Medicine, Translational Research
|
Leave a comment
NICE Supports NHS Free Trial Access to Medical Research in Journals and Ebooks (NICE)
Summary NHS staff working in England, Scotland, Wales and Northern Ireland have (for a trial period) free access to articles containing current information about research and best practice published in a massive range of medical and scientific journals. This development follows recommendations in the government-commissioned … Continue reading →
Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), National, NHS, Northern Ireland, Scotland, UK, Wales
|
Tagged AAAS, Alzheimer's Research, Annual Reviews, Brain Research, Building Research Capacity, Community Research, Dame Janet Finch CBE, Dementia Research, Developing Research Skills, Elsevier, Finch Report: Accessibility Sustainability Excellence, Finch Report: Report of the Working Group on Expanding Access to Published Research Findings, Free Open Access Ebooks, Free Open Access Journals, Genetic Research, Institute of Physics, IOP Publishing, Joint Information Systems Committee (Jisc), Medical Research, Medical Research Council (MRC), National Institute for Health and Care Excellence (NICE), Nature Publishing Group, Neurodegenerative Disease Research, Neurological Research, NHS Education for Scotland, NHS Evidence: A-Z Journals List, NICE, Open Access Ebooks, Open Access Journals, Open Access Research, Oxford University Press, Pharmacological Research, Public Health Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Into Aging, Researcher Access to Data, Resources for Researchers, Royal Society of Chemistry, Springer, Working Group on Expanding Access to Published Research Findings
|
Leave a comment
Drug Discovery Institute (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has announced proposals to create Europe’s first Drug Discovery Institute for neurodegenerative diseases including dementia. The aim of the multi-million pound Drug Discovery Institute will be to accelerate progress towards effective treatments for Alzheimer’s disease and other dementias. … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, For Researchers (mostly), International, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Commissioning Research, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Dr Simon Ridley, Drug Discovery Institute, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, International Collaborations, International Organisations, International Programmes, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Pharmacological Research, Research Commitment, Research Consortia, Research Culture, Research Mapping, Research Programmes, Scientific Management Board of the Drug Discovery Institute, Translational Research
|
Leave a comment
